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Cost comparison of insulin glargine with insulin detemir
in a basal-bolus regime with mealtime insulin aspart in
type 2 diabetes in Germany
KostenvergleichvonInsulinglarginmitInsulindetemirimRahmeneiner
Basis-Bolus-Behandlung (ICT) mit mahlzeitenbezogenem Insulin aspart
bei Typ-2-Diabetes in Deutschland
Abstract
Objective: To compare the treatment costs of insulin glargine (IG;
Lantus
®) to detemir (ID; Levemir
®), both combined with bolus insulin
aspart (NovoRapid
®) in type 2 diabetes (T2D) in Germany.
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Methods: Cost comparison was based on data of a 1-year randomised
controlled trial [1]. IG was administered once daily and ID once (57% Aileen Rae Neilson
2
of patients) or twice daily (43%) according to treatment response. At
the end of the trial, mean daily basal insulin doses were 0.59 U/kg (IG)
1 Klinikum Traunstein,
Germany
and 0.82 U/kg (ID). Aspart doses were 0.32 U/kg (IG) and 0.36 U/kg
(ID).CostswerecalculatedfromtheGermanstatutoryhealthinsurance
2 HealthEcon AG, Basel,
Switzerland
(SHI) perspective using official 2008 prices. Sensitivity analyses were
performed to test robustness of the results.
Results: Annual basal and bolus insulin costs per patient were € 1,473
(IG) and € 1,940 (ID). The cost of lancets and blood glucose test strips
3 Sanofi-Aventis Deutschland
GmbH, Berlin, Germany
were€1,125(IG)and€1,286(ID).Annualcostsforneedleswere€393
(IG) and € 449 (ID). The total annual cost per patient of administering
IG was € 2,991 compared with € 3,675 for ID, translating into a 19%
annualcostdifferenceof€684/patient.Basecaseresultswererobust
to varying assumptions for insulin dose, insulin price, change in weight
and proportion of ID once daily administrations.
Conclusion:IGandIDbasal-bolusregimeshavecomparativesafetyand
efficacy, based on the Hollander study, IG however may represent a
significantlymorecostsavingoptionforT2DpatientsinGermanyrequir-
ing basal-bolus insulin analogue therapy with potential annual cost
savings of € 684/patient compared to ID.
Keywords: insulin glargine, insulin detemir, basal insulin, type 2
diabetes, cost analysis
Zusammenfassung
Ziel: Vergleich der Behandlungskosten von Insulin glargin (IG; Lantus
®)
und Insulin detemir (ID; Levemir
®) jeweils in Kombination mit Bolusin-
sulin aspart (NovoRapid
®) bei Typ-2-Diabetes (T2D) in Deutschland.
Methoden:DerKostenvergleichbasierteaufdenDateneinereinjährigen
randomisierten, kontrollierten klinischen Studie [1]. IG wurde einmal
täglich verabreicht und ID einmal (57% der Patienten) oder zweimal
täglich(43%)inAbhängigkeitvomAnsprechenaufdieBehandlung.Die
durchschnittliche Dosierung des Basalinsulins betrug 0,59 IE/kg (IG)
und 0,82 IE/kg (ID) pro Tag. Die durchschnittliche Dosierung für Aspart
betrug 0,32 IE/kg (IG-Patienten) und 0,36 IE/kg (ID-Patienten). Die
KostenwurdenausdemBlickwinkelderGesetzlichenKrankenversiche-
rung unter Verwendung offizieller Preise für 2008 berechnet. Die Ro-
bustheit der Ergebnisse wurde anhand von Sensitivitätsanalysen
überprüft.
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Research Article OPEN ACCESSErgebnisse: Die jährlichen Kosten für Basal- und Bolusinsulin betrugen
€ 1.473 (IG) und € 1.940 (ID) pro Patient. Die Kosten für Lanzetten und
Blutzucker-Teststreifen beliefen sich auf € 1.125 (IG) und € 1.286 (ID).
Die Kosten für Nadeln betrugen € 393 (IG) und € 449 (ID) pro Patient
und Jahr. Die Anwendung von IG war damit insgesamt mit Kosten von
€ 2.991 pro Patient und Jahr verbunden, die von ID mit Kosten von
€3.675,worauseinKostenunterschiedvon19%oder€684/proPatient
und Jahr resultiert. Die Ergebnisse des Basisszenarios zeigten sich ro-
bust gegenüber veränderten Annahmen hinsichtlich Insulindosis, Insu-
linpreis,GewichtsveränderungundAnteilPatientenmiteinmaltäglicher
Verabreichung von ID.
Schlussfolgerungen:BasierendaufderklinischenStudievonHollander
sind Basal-Bolus-Behandlungsregime, die auf IG und ID aufbauen, hin-
sichtlich Sicherheit und Wirksamkeit vergleichbar. Die Behandlung mit
IG jedoch ist gegenüber ID mit einer potentiellen Einsparung von € 684
pro Patient und Jahr verbunden.
Schlüsselwörter: Insulin glargin, Insulin detemir, Basalinsulin,
Typ-2-Diabetes, Kostenanalyse
Introduction
Insulintherapyinpatientswithtype2diabetes(T2D)has
significantclinicalandcostimplications.Therandomised
controlled trial (RCT) recently published by Hollander [1]
comparedtheefficacyandsafetyofthelong-actingbasal
analogues glargine and detemir used in a basal-bolus
treatment regime for T2D patients previously receiving
other insulin and/or oral antidiabetic drugs (OADs). The
multi-national, open-label, parallel-group, treat-to-target,
non inferiority study demonstrated at 52 weeks, that
therewasnosignificantdifferenceintermsoftheprimary
efficacy endpoint of mean HbA1c. Both basal insulins
were associated with a comparable clinically relevant re-
duction in hyperglycemia. At the end of the trial detemir
was associated with less weight gain despite a higher
total insulin dose than glargine (not significant).
The RCT included 319 subjects from 56 sites in Europe
and the US. Eligible patients for inclusion were men and
women aged ≥18 years, a diagnosis of T2D for ≥12
months,aBMI≤40.0kg/m
2,aglycosylatedhaemoglobin
(HbA1c) of 7.0% to ≤11.0% at screening, and had been
receivinganyOADsregimeorinsulinwithorwithoutOADs
for >4 months. In the RCT patients were randomised in
a 2:1 ratio to receive either detemir (n=214) or glargine
(n=105).Demographicandbaselinecharacteristicswere
comparable between detemir and glargine groups:
% male: 60.7% vs. 52.4%; mean age (years): 59 vs. 58,
mean weight (kg): 93.3 vs. 91.5; duration of diabetes
(years):13.6vs.13.4years;meanHbA1c:8.6vs.8.8[1].
ExistingOADswerecontinued,andpatientswerestratified
by OAD. Patients receiving detemir were transferred to
twice-daily dosing if titration of the evening dose did not
result in a mean pre-breakfast and pre-dinner plasma
glucose level of ≤6.0 mmol/L. Patients in the glargine
group continued on once-daily dosing, according to la-
belled usage. In both groups insulin aspart was admin-
istered immediately before each main meal. The propor-
tionofpatientsreceivingdifferentantidiabetictreatments
at baseline was comparable in the detemir and glargine
groups: insulin + OAD (43.5% vs. 51.4% respectively);
insulinonly(36.9%vs.32.4%);OADonly(19.6%vs.16.2%
respectively) [1].
The objective of the present study was to determine
whether the use of insulin glargine (IG) would result in
different total direct costs in comparison with insulin de-
temir (ID) in a basal-bolus regime (ICT) with mealtime in-
sulin aspart in T2D patients in Germany.
Anearliercostanalysiscomparingbasalinsulinanalogues
glargine versus detemir in combination with oral antidia-
betic drugs (basal supported oral therapy; BOT) in insulin
naive T2D patients in Germany based on the findings of
the Rosenstock trial [2] has been conducted from the
perspective of the statutory health insurance (SHI) in
Germany [3] and other countries [4], [5], [6], [7], [8].
Sincetransferabilityfromonecountrytoanotherisusually
restricted, country-specific evaluations are required that
take into account country-specific features such as epi-
demiology of diabetes, treatment guidelines, patterns of
health service (resource) use, unit costs and reimburse-
ment regulations [9].
The purpose of the current study was to perform a cost
comparison based on the results of the Hollander trial
[1] for once-daily insulin glargine or once- or twice daily
basalinsulindetemirbothcombinedwithmealtimeaspart
(basal-bolus therapy) in adults with T2D for the German
setting. These results therefore provide estimates of po-
tentialdifferencesindirecthealthcarecostsbetweenthe
two therapeutic regimes in Germany.
A cost analysis in which only the costs of the alternative
treatmentstrategiesarecomparedisajustifiedeconomic
evaluation method in the current study since evidence
from the RCT [1] demonstrated that the alternative
strategy is at least clinically equivalent (non inferiority
trial). Such economic evaluation approaches are useful
to support decision making on the financing of insulin
therapies for patients with T2D in different healthcare
settings.
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The present study conducted a direct cost comparison
between the two different basal-bolus treatment
strategies based on the findings of the RCT [1] for the
German healthcare setting. A number of additional as-
sumptionsmadeinthemodellinganalysishaveacertain
degree of uncertainty, but in general the values chosen
forcalculationadoptedaconservativeapproach,generally
biased against the treatment arm with insulin glargine.
Cost-minimisation-analysisisavalidanalyticaleconomic
framework for the current study given the assumption of
non-inferiority as demonstrated by the patients of the
Hollander trial [1]. The cost analysis was performed ac-
cordingtoGermangoodpracticerecommendationsbased
on the economic evaluation methods of the Institute for
Quality and Efficiency in HealthCare (IQWiG) [10], on
Health Economic Evaluation: third and updated version
of the Hannover Consensus [11], and internationally in
relation to conducting cost assessments [12].
Perspective and time horizon
The economic analysis involved an assessment of direct
healthcare costs only and therefore takes the cost per-
spective of the German statutory health insurance (SHI).
The time period is the first year after initiating insulin
basal-bolus treatment.
Cost determinants
Identification,measurementandvaluationofthekeycost
determinants comprise the main activities in conducting
a pharmacoeconomic analysis. In the present study, all
unitcostsweretakenfromofficialpricelistsandsources
basedontheyear2008.Thecostdeterminantsthatwere
included, resource utilisation in each case, and the unit
costs applied, are presented in detail below. The calcula-
tions characterise the base case of the cost analysis and
were further investigated in sensitivity analyses. All key
modelassumptionsusedintheanalysesaresummarised
in Table 1.
Basal insulin analogues
The final insulin doses at the end of the RCT [1] were
used for the base case analysis. These applied to con-
sumptionofglargine,detemirandaspart.Itwasassumed
that the average final dose of each insulin over the 52
weeks treatment period and calculations of mean doses
were based on patient’s final weights. The RCT [1] did
not report the mean insulin starting doses for glargine
and detemir, but reported that the basal insulins were
titrated individually throughout the trial to reach and
maintain pre-breakfast and pre-dinner plasma glucose
levels of ≤6.0 mmol/L (108 mg/dL) without hypo-
glycaemia. Similarly, insulin aspart was initiated and ad-
justed according to local practice to achieve a 2-hour
postprandial plasma glucose target of ≤9.0 mmol
(162 mg/dL).
Insulin glargine is available on the German market as
Lantus
® (Lantus is a registered trademark of Sanofi-
Aventis). The formulation for insulin detemir used in the
trial was Levemir
® (Levemir is a registered trademark of
NovoNordisk).Specificdetailsontheactualdevicesused
were not reported in the trial itself. For the analysis, we
considered only the insulin and not the devices or pens
as these are usually given to the patients free of charge
as a sample. Each pen can be filled with cartridges with
3 ml solution (1 ml contains 100 U). In addition the price
differencesbetweenthecompareddevicesareverysmall.
For insulin prices, see Table 1. For all three drugs we as-
sumed the price of the most economical pack size, i.e.:
insulin glargine (cartridge: 2700 IU, 9x3 ml); insulin de-
temir (cartridge: 3000 IU, 10x3 ml); insulin aspart (cart-
ridge: 3000 IU, 10x3 ml). Prices were taken as the phar-
macy sales price according to Lauer Taxe including value
addedtax(VAT)asreimbursedbySHI[13].Manufacturer
rebates(6%)andpharmacyrebates(€2.30perprescrip-
tion) were of no importance in this comparison.
Oral antidiabetic drugs, (metformin, insulin
secretagogues, α-glucosidase inhibitors)
On the basis of the RCT study protocol, the use of OADs
wasrecommendedtoremainstableduringthestudyand
no actual data reported in the article to the contrary.
Thereforeweassumedtheseitemsofresourceutilisation
to be the same in both groups, and thus did not include
them in the current cost assessment.
Consumableitems:needles,bloodglucosetest
strips and lancets
With respect to the number of needles, test strips and
lancetsneededperpatientweestimatedasonepereach
insulin injection. However, findings from a recent
European diabetes patient survey reported that 93% of
men with diabetes in Germany used the same needle
several times, on average 9.2 injections with the same
needle [14], so we tested this in a sensitivity analysis.
ClickFine
® (Clickfine is a registered trademark of Yp-
somed,Germany)needleswereassumedforbothregimes
as these can be fitted in all makes of pen. The manufac-
turer’srecommendedpricewasusedasthebasisforthe
cost calculations [15]. One lancet and one glucose test
strip is required for each blood glucose measurement.
Thus,inthebasecase,threemeasurementsperdaywere
assumedlinkedtotheaspartapplication,oneforglargine
and either one or two for detemir. Following the results
in the underlying RCT [1] we assumed that 57% of pa-
tients received twice daily injections with detemir. It was
assumedthatSoftclix
®(Softclixisaregisteredtrademark
ofRocheDiagnostics)lancetswereused.Asawiderange
of blood glucose test strips are available at almost
identicalprices,auniformprice[16]couldbeestablished
sothatcostwasindependentofanyparticularmeasuring
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system(seeTable1).Theseassumptionstoowerevaried
in the sensitivity analyses.
Further resource utilisation
In the RCT, the risk of reported major hypoglycemic epi-
sodesandotheradverseeventswascomparablebetween
treatment regimes. Major hypoglycemic events were ex-
periencedby4.7%ofdetemirpatientsand5.7%glargine
patients. The corresponding results for adverse events
were 86.4% and 83.8% respectively. Serious adverse
eventswere14.5%and13.3%respectively.Wetherefore
assumed no difference in these related costs in our
analysis between the two therapeutic groups.
Data management and calculations
Data on resource use and unit costs were entered into
Microsoft Excel 2003 spreadsheets. All calculations as
well as presentation of results were done using prices
(Euro) to two decimal places. Calculations, tables and
graphs were generated using Microsoft Excel 2003.
Allowanceforparameteruncertainty:sensitivity
analysis
Weperformedanumberofsensitivityanalysestoexplore
the robustness of the study results to changes in the
value of key cost parameter estimates.
First, the assumptions made in the base case analysis
werevariedinsimpleone-waysensitivityanalysesinorder
to test the robustness of the base case results to alter-
native assumptions in price, resource use, uncertainty in
other assumptions and possible deviations from the
underlying RCT results for routine medical care. In the
first part of the sensitivity analyses, the most important
cost determinants were altered independently of one
another by ±25% around their base case values.
Additionally, since mean weight gain at 52 weeks was
significantlylowerwithdetemirthanwithglargine(2.8kg
vs. 3.8 kg) we also explored the impact of varying the
mean weight gain by ±25%: glargine across the range
2.85 kg to 4.75 kg; detemir across the range 2.1 kg to
3.5 kg. Specifically, this was expected to have some im-
pact on insulin resource use and hence insulin related
costs, even if the RCT publication reports no change in
insulin use correlating to a change of weight of patient
in the course of the study [1].
This set of one-way sensitivity analyses are summarised
in a tornado plot showing the cost drivers in descending
order of importance. Secondly, a number of modified
scenarios were carried out to test specifically variations
more applicable to routine care in Germany. These vari-
ations included: all detemir patients received once-daily
injections; replacing detemir with NPH (and price) with
theproportionofoncedailytotwicedailyinjectionsbased
ontherecentobservationaltrialinGermany[17];number
of blood glucose measurements and needles utilised.
Results
Base case analysis
The base case results are presented in Table 2. Once-
dailyinsulinglargineincombinationwithmealtimeaspart
generated total annual therapy costs of € 2,991 com-
paredto€3,675forpatientsreceivingtheinsulindetemir
basal-bolusregime.Thus,averagecostsavingsamounting
to € 684 (approx. 19% reduction) per patient per year in
favour of the glargine group were generated. The most
important cost component explaining the overall differ-
ence in total annual costs were the lower insulin costs
(by € 467) followed by lower costs of blood glucose
measurementsincludingteststrips,lancetsandneedles
(by € 217). Insulin comprised the largest proportional
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cost for both treatment regimes: 49% vs. 53% for insulin
glargine and insulin detemir respectively.
Sensitivity analysis
UnivariatesensitivityanalysisaresummarisedinFigure1
as a tornado diagram showing the cost savings of insulin
glargineresultingfromchangesindifferentcostdetermin-
antsandvariedassumptions.Thelengthofthehorizontal
bars (x-axis) corresponds to the difference in average
costs between glargine and detemir groups over the
specified variables of interest depicted on the y-axis. The
vertical line transecting the bars represents the cost dif-
ference between the groups in the point-estimate
(average) base case. The base case with a cost saving of
€ 684 per patient per year is represented by the central
axis. The tornado diagram ranks the cost parameters
based on the magnitude of their impact on the cost dif-
ferences between the two treatment groups. The results
show clearly that the insulin consumptions and insulin
price have the highest impact. Several reports regarding
higherdoserequirementsofinsulindetemirversusinsulin
glargine support the findings [18], [19], [20], [21]. For all
these variations, cost advantages and thus real cost
savingswereseenwithinsulinglarginebasalbolusregime
(range of cost savings is € 331–€ 1,037). Factors with
the least influence included price (unit costs) of needles,
test strips and lancets as well as gain in weight. For ex-
ample, increasing the weight gain in the glargine group
(3.8 kg) by 25%, shifted the final weight from 95.3 kg to
96.25kg,andmeandailytotalinsulinglarginedosefrom
56.2 units to 56.8 units. Thus, total glargine insulin re-
lated costs were increased by <1% (€ 1,007 to € 1,018)
and decreased total costs savings from € 684 to € 669.
On the other hand, decreasing the weight gain in the de-
temirgroup(2.8kg)by25%,shiftedthefinalweightfrom
96.1 to 95.4 kg, and mean daily total detemir dose from
78.8 to 78.23 units. Total detemir insulin related costs
were decreased by <1% (€ 1,411 to €1,401) and total
costsavingsreducedfrom€684to€670.Finally,increas-
ing or decreasing the proportion of detemir patients re-
ceiving once-daily insulin injections, i.e. from 42.8% to
53.5% (+25%), or from 42.8% to 32.1% (–25%), had
moderateimpactwithannualcostsavingsmovingranging
€ 628 to € 805.
One-way sensitivity analysis on price assumptions for
lancets and needles covered the range of published po-
tential unit prices. Only in the case of glucose test strips
was there still a potentially lower price (€ 0.43/test strip)
[22] than the assumed price when the minus 25% as-
sumptionwasapplied(€0.49/teststrip).Usingthelower
price reduced total annual cost savings by 7% (i.e. from
€ 684 to € 637).
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(Parameter variation ±25% around base case values)
Table 3: Sensitivity analysis: results with modified scenarios
Further modified scenarios to investigate assumptions
moreapplicabletoroutinecareconfirmedtherobustness
of the base case results (Table 3). All scenarios still
yielded considerable cost savings for the insulin glargine
group compared to the insulin detemir group.
Discussion
The clinical results from the Hollander RCT [1] showed
that efficacy of glargine compared with detemir both
combined with mealtime aspart, were of comparable ef-
ficacy in improving overall metabolic control. However,
after 52 weeks treatment, weight gain with detemir was
slightly lower than with glargine. On the other hand, de-
temirwasassociatedwithahigherbasalandbolusinsulin
dose compared to glargine. The results of our cost
analysis comparing the direct treatment costs between
the two regimes showed lower annual costs per patient
for Germany in favour of insulin glargine. The results of
this cost comparison are consistent with the findings of
furtherrecentGermancostcomparisonsbetweeninsulin
glargineandinsulindetemirsuchastheRosenstockRCT
[3], the LIVE-COM study [17], the LIVE-KK study [23] and
findings from other countries [4], [5], [6], [7], [8].
A limitation of the current study might be that resource
use had to be derived from a RCT setting that might not
mirror every day practice. There may be a number of
characteristics of the trial setting that might be different
inactualGermanclinicalpracticecontextworthyoffurther
exploration.Wetriedtoovercomethisproblembyvarying
resource use in various sensitivity analyses. Our range
of modified scenarios showed that the cost advantages
withglarginewererobusttoarangeofplausiblevariations
in base case assumptions. However, it would be helpful
to perform a calculation on the basis of observational
data.
Further support to the finding that insulin glargine-based
regimes are cost saving was demonstrated in a recent
retrospective analysis of three years claims data (over
years 2006–2008) among patients with type 1 and type
2 diabetes in Germany receiving insulin detemir and in-
sulin glargine based regimes [24]. Based on resource
use in an actual real-life practice setting, the study de-
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insulins, OADs, test strips, lancets and needles. The
authors reported that the annual direct costs for insulin
glargine were lower than for insulin detemir (€ 1,282
versus € 1,818, which is a mean cost saving difference
of € 536). Compared to our results we estimated an an-
nual cost saving of € 684 in direct costs with insulin
glargine based on the Hollander trial. It is notable that
the absolute costs based on the Hollander trial were
higher in our analyses (i.e. glargine: € 2,992 versus
€ 1,282; detemir: € 3,676 versus € 1,818). A possible
explanationforthesedifferencesmaybeduetotheactual
existenceofdifferencesinresourceusebetweenpatients
with diabetes participating in a clinical trial setting and
diabetespatientsinactualclinicalpractice[25],[26].For
example, Dixon [25] reported that “... pivotal trials of
glargine (for the treatment of type 1 and type 2 diabetes)
designed specifically to show non-inferiority with the
comparator insulin, may not show the true value of glar-
gine which was found to be less costly and resulted in
improved outcomes in real-life use than detemir...”. Also,
based on data from a proprietary database of people
treatedingeneralpracticeintheUK(TheHealthImprove-
mentNetwork(THIN))Poole[26]reportedthatthemedian
annual cost of treatment with glargine and detemir for
people with type 2 diabetes was £ 1,014 versus £ 1,410
(∆=28%; p<0.001), respectively. In type 2 diabetes, a
glargine-based regimen also resulted consistently in re-
duced costs of treatment: “...insulin (32%; p<0.001), re-
agents(16%;p=0.002),hypoglycaemiarescuemedication
(34%; p=0.260), pen delivery devices (40%; p<0.001)
and sharps (17%; p=0.006)...” and there was also no
statistically significant increase in cost of treatment with
oralhypoglycaemicagentsusingaglargine-basedregime.
In a recent cost analysis in type-1-diabetes [27] during
thefirstyearaftertheswitchtotherespectivelongacting
insulinaspartofbasal-bolustherapywithinsulinglargine
or determir showed cost savings not only resulting from
differences in the application frequency (once or twice
daily)butmainlyfromthelowerinsulindosageofglargine
compared to detemir. This is also true in T2D patients in
our current analysis.
Nonetheless,bothtrialbasedcostcomparisonsforinsulin
glargine and insulin detemir [3], [4], [5], [6], [7], [8] as
well as comparisons based on “real-life” data [23], [24],
[28] have consistently reported a cost-advantage for
glarginebasedregimes.Moreover,clinicaltrialsdesigned
to specifically show non-inferiority with the comparator
insulin, may not show the true value of glargine in real-
lifeusethandetemir[25].Ontheotherhand,IQWIGnotes
thetime-horizonlimitationofeconomicdata(if)collected
in clinical trials [29] “... these data are often insufficient
for the comprehensive costing of a health technology.
Clinicaltrialsseldomprovideinformationonthelong-term
consequences of a technology. In addition, they do not
always adequately and comprehensively reflect all cost
aspects relevant to the German health care setting [30],
[31]. Moreover, protocol-induced resource consumption
inclinicaltrialsmaybiascostestimation.Thus,modelling
theeffectsofahealthtechnologyisanessentialcompon-
ent of health economic evaluations...”
In the sensitivity analysis we included an alternative
scenario which involved the assumption of one blood
glucose measurement daily in both groups (Table 3). The
annual costs of both treatments were changed but the
overall conclusion remains unchanged, that is that pa-
tientstreatedwithglargineyieldcostsavings.Theannual
cost of glargine is reduced from € 2,991 to € 2,429 and
for detemir from € 3,675 to € 2,952. The cost saving is
thereforereducedfrom€684to€523.Adoptinganeven
more conservative approach and eliminating any differ-
ences in costs due to blood glucose measurements, as
disposable items as a whole, then cost savings are re-
duced to of € 467 and are associated with differences
in insulin consumption alone.
In the Hollander RCT publication [1] the authors stated
in the methods that “...existing OAD regimens were con-
tinued, and patients were stratified by OAD treatment...”.
However, it may well be the case that patients receiving
treatment including OADs at baseline may have changed
during the course of the trial since no details are given
in the Hollander article itself. Therefore it should be ac-
knowledged that there remains some uncertainty sur-
roundingtheobserved(verysimilar)clinicaleffectssince
any changes (or otherwise) in treatment with OADs is not
reported.
The Hollander trial reported that after 52 weeks of treat-
ment, patients receiving detemir experienced a signifi-
cantly lower weight gain compared to the glargine group
(2.8vs.3.8kg,respectively;meandifference–1.04).This
resultmayhavepossibleimplicationsforinsulin-consump-
tion over the long-term and any impact on differences in
resource use should be considered in future economic
analyses over a longer time horizon than the short
12 months of the current study.
Inthecontextofglargineversusdetemirinthetreatment
oftype2diabetes,anumberofrecentstudiessuggested
in addition cost-effectiveness advantages in favour of
basal analogue insulin glargine compared with detemir
due to improved outcome parameters [32], [33], [34].
This is also an important area for future research to the
German-specificsettingwithregardevaluatingtherelative
costs and benefits of basal-bolus regimes in T2D.
Conclusion
In Germany, insulin glargine combined with mealtime
aspart is associated with annual cost savings of
€ 684/patient (around 20%) compared to the use of in-
sulin detemir basal bolus therapy. These findings are ro-
bust to variations in key model parameter assumptions.
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